市場調査レポート
商品コード
1373465

核酸医薬品の世界市場:~2029年

Global Nucleic Acid Drugs Market Insights, Forecast to 2029

出版日: | 発行: QYResearch | ページ情報: 英文 156 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円
核酸医薬品の世界市場:~2029年
出版日: 2023年11月06日
発行: QYResearch
ページ情報: 英文 156 Pages
納期: 2~3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の核酸医薬品の市場規模は、2023年の124億8,673万米ドルから、予測期間中は3.71%のCAGRで推移し、2029年には155億3,836万米ドルの規模に成長すると予測されています。

地域別では、米国・カナダ市場は、2023年の43億5,770万米ドルから、10.46%のCAGRで推移し、2029年には79億1,760万米ドルに達すると予測されています。一方、欧州市場は、2023年の55億7,025万米ドルから、-4.24%のCAGRで推移し、2029年には42億9,509万米ドルとなると予測されています。

世界の上位5社による2022年の収益シェアは約97.87%に達しました。

当レポートでは、世界の核酸医薬品の市場を調査し、市場および製品の概要、競合情勢、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、価格動向、市場成長への各種影響因子の分析、主要企業の分析などをまとめています。

目次

第1章 レポート概要

  • 調査範囲
  • タイプ別市場分析
    • 成長率:2018 vs 2022 vs 2029
    • アンチセンスオリゴヌクレオチド (ASO) 医薬品
    • 低分子干渉RNA (siRNA) 薬
    • mRNA医薬品
  • 用途別市場
    • 市場シェア:2018 vs 2022 vs 2029
    • 神経筋疾患
    • hATTR
    • COVID-19
  • 前提・制限
  • 調査目的
  • 調査年数

第2章 世界の成長動向

  • 世界市場の展望
  • 世界の成長動向:地域別
    • 市場規模:2018 vs 2022 vs 2029
    • 市場規模の推移
    • 市場規模の予測
  • 市場力学
    • 産業動向
    • 市場促進要因
    • 市場課題
    • 市場抑制要因

第3章 競合情勢:主要企業別

  • 収益・収益シェア:主要企業別
  • 世界の主要企業:企業タイプ別
  • 世界の主要企業の収益ランキング
  • 市場集中率 (CR5)
  • 世界の主要企業:本社およびサービス提供エリア
  • 世界の主要企業:製品・用途
  • 世界の主要企業:設立日
  • M&A・拡張計画

第4章 核酸医薬品市場の内訳データ:タイプ別

  • 市場規模の推移・予測

第5章 核酸医薬品市場の内訳データ:用途別

  • 市場規模の推移・予測

第6章 北米

第7章 欧州

第8章 中国

第9章 アジア (中国を除く)

第10章 中東・アフリカ・ラテンアメリカ

第11章 主要企業のプロファイル

  • Sarepta Therapeutics
  • Ionis Pharmaceuticals
  • Alnylam
  • Biogen
  • Nippon Shinyaku
  • Sobi
  • Novartis
  • BioNTech
  • Pfizer
  • Moderna Therapeutics
  • Jazz Pharmaceuticals
  • CureVac
  • Regulus Therapeutics
  • ProQR
  • Secarna
  • MiNA Therapeutics
  • Sylentis
  • Arrowhead
  • Silence Therapeutics
  • Dicerna

第12章 アナリストによる見解・総論

第13章 付録

図表

List of Tables

  • Table 1. Global Nucleic Acid Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
  • Table 2. Global Nucleic Acid Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
  • Table 3. Global Nucleic Acid Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
  • Table 4. Global Nucleic Acid Drugs Market Size by Region (2018-2023) & (US$ Million)
  • Table 5. Global Nucleic Acid Drugs Market Share by Region (2018-2023)
  • Table 6. Global Nucleic Acid Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
  • Table 7. Global Nucleic Acid Drugs Market Share by Region (2024-2029)
  • Table 8. Nucleic Acid Drugs Market Trends
  • Table 9. Nucleic Acid Drugs Market Drivers
  • Table 10. Nucleic Acid Drugs Market Challenges
  • Table 11. Nucleic Acid Drugs Market Restraints
  • Table 12. Global Nucleic Acid Drugs Revenue by Players (2018-2023) & (US$ Million)
  • Table 13. Global Nucleic Acid Drugs Market Share by Players (2018-2023)
  • Table 14. Global Top Nucleic Acid Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid Drugs as of 2021)
  • Table 15. Global Nucleic Acid Drugs Industry Ranking 2021 VS 2022
  • Table 16. Global 5 Largest Players Market Share by Nucleic Acid Drugs Revenue (CR5 and HHI) & (2021-2023)
  • Table 17. Global Key Players of Nucleic Acid Drugs, Headquarters and Area Served
  • Table 18. Global Key Players of Nucleic Acid Drugs, Product and Application
  • Table 19. Global Key Players Product Type
  • Table 20. Global Key Players Established Date
  • Table 21. Mergers & Acquisitions, Expansion Plans
  • Table 22. Global Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
  • Table 23. Global Nucleic Acid Drugs Revenue Market Share by Type (2018-2023)
  • Table 24. Global Nucleic Acid Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
  • Table 25. Global Nucleic Acid Drugs Revenue Market Share by Type (2024-2029)
  • Table 26. Global Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
  • Table 27. Global Nucleic Acid Drugs Revenue Market Share by Application (2018-2023)
  • Table 28. Global Nucleic Acid Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
  • Table 29. Global Nucleic Acid Drugs Revenue Market Share by Application (2024-2029)
  • Table 30. North America Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
  • Table 31. North America Nucleic Acid Drugs Market Size by Type (2024-2029) & (US$ Million)
  • Table 32. North America Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
  • Table 33. North America Nucleic Acid Drugs Market Size by Application (2024-2029) & (US$ Million)
  • Table 34. North America Nucleic Acid Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 35. North America Nucleic Acid Drugs Market Size by Country (2018-2023) & (US$ Million)
  • Table 36. North America Nucleic Acid Drugs Market Size by Country (2024-2029) & (US$ Million)
  • Table 37. Europe Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
  • Table 38. Europe Nucleic Acid Drugs Market Size by Type (2024-2029) & (US$ Million)
  • Table 39. Europe Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
  • Table 40. Europe Nucleic Acid Drugs Market Size by Application (2024-2029) & (US$ Million)
  • Table 41. Europe Nucleic Acid Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 42. Europe Nucleic Acid Drugs Market Size by Country (2018-2023) & (US$ Million)
  • Table 43. Europe Nucleic Acid Drugs Market Size by Country (2024-2029) & (US$ Million)
  • Table 44. China Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
  • Table 45. China Nucleic Acid Drugs Market Size by Type (2024-2029) & (US$ Million)
  • Table 46. China Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
  • Table 47. China Nucleic Acid Drugs Market Size by Application (2024-2029) & (US$ Million)
  • Table 48. Asia Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
  • Table 49. Asia Nucleic Acid Drugs Market Size by Type (2024-2029) & (US$ Million)
  • Table 50. Asia Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
  • Table 51. Asia Nucleic Acid Drugs Market Size by Application (2024-2029) & (US$ Million)
  • Table 52. Asia Nucleic Acid Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
  • Table 53. Asia Nucleic Acid Drugs Market Size by Region (2018-2023) & (US$ Million)
  • Table 54. Asia Nucleic Acid Drugs Market Size by Region (2024-2029) & (US$ Million)
  • Table 55. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2018-2023) & (US$ Million)
  • Table 56. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2024-2029) & (US$ Million)
  • Table 57. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2018-2023) & (US$ Million)
  • Table 58. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2024-2029) & (US$ Million)
  • Table 59. Middle East, Africa, and Latin America Nucleic Acid Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 60. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2018-2023) & (US$ Million)
  • Table 61. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2024-2029) & (US$ Million)
  • Table 62. Sarepta Therapeutics Company Details
  • Table 63. Sarepta Therapeutics Business Overview
  • Table 64. Sarepta Therapeutics Nucleic Acid Drugs Product
  • Table 65. Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 66. Sarepta Therapeutics Recent Development
  • Table 67. Ionis Pharmaceuticals Company Details
  • Table 68. Ionis Pharmaceuticals Business Overview
  • Table 69. Ionis Pharmaceuticals Nucleic Acid Drugs Product
  • Table 70. Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 71. Ionis Pharmaceuticals Recent Development
  • Table 72. Alnylam Company Details
  • Table 73. Alnylam Business Overview
  • Table 74. Alnylam Nucleic Acid Drugs Product
  • Table 75. Alnylam Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 76. Alnylam Recent Development
  • Table 77. Biogen Company Details
  • Table 78. Biogen Business Overview
  • Table 79. Biogen Nucleic Acid Drugs Product
  • Table 80. Biogen Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 81. Biogen Recent Development
  • Table 82. Nippon Shinyaku Company Details
  • Table 83. Nippon Shinyaku Business Overview
  • Table 84. Nippon Shinyaku Nucleic Acid Drugs Product
  • Table 85. Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 86. Nippon Shinyaku Recent Development
  • Table 87. Sobi Company Details
  • Table 88. Sobi Business Overview
  • Table 89. Sobi Nucleic Acid Drugs Product
  • Table 90. Sobi Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 91. Sobi Recent Development
  • Table 92. Novartis Company Details
  • Table 93. Novartis Business Overview
  • Table 94. Novartis Nucleic Acid Drugs Product
  • Table 95. Novartis Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 96. Novartis Recent Development
  • Table 97. BioNTech Company Details
  • Table 98. BioNTech Business Overview
  • Table 99. BioNTech Nucleic Acid Drugs Product
  • Table 100. BioNTech Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 101. BioNTech Recent Development
  • Table 102. Pfizer Company Details
  • Table 103. Pfizer Business Overview
  • Table 104. Pfizer Nucleic Acid Drugs Product
  • Table 105. Pfizer Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 106. Pfizer Recent Development
  • Table 107. Moderna Therapeutics Company Details
  • Table 108. Moderna Therapeutics Business Overview
  • Table 109. Moderna Therapeutics Nucleic Acid Drugs Product
  • Table 110. Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 111. Moderna Therapeutics Recent Development
  • Table 112. Jazz Pharmaceuticals Company Details
  • Table 113. Jazz Pharmaceuticals Business Overview
  • Table 114. Jazz Pharmaceuticals Nucleic Acid Drugs Product
  • Table 115. Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023) & (US$ Million)
  • Table 116. Jazz Pharmaceuticals Recent Development
  • Table 117. CureVac Company Details
  • Table 118. CureVac Business Overview
  • Table 119. CureVac Nucleic Acid Drugs Product
  • Table 120. CureVac Recent Development
  • Table 121. Regulus Therapeutics Company Details
  • Table 122. Regulus Therapeutics Business Overview
  • Table 123. Regulus Therapeutics Nucleic Acid Drugs Product
  • Table 124. Regulus Therapeutics Recent Development
  • Table 125. ProQR Company Details
  • Table 126. ProQR Business Overview
  • Table 127. ProQR Nucleic Acid Drugs Product
  • Table 128. ProQR Recent Development
  • Table 129. Secarna Company Details
  • Table 130. Secarna Business Overview
  • Table 131. Secarna Nucleic Acid Drugs Product
  • Table 132. Secarna Recent Development
  • Table 133. MiNA Therapeutics Company Details
  • Table 134. MiNA Therapeutics Business Overview
  • Table 135. MiNA Therapeutics Nucleic Acid Drugs Product
  • Table 136. MiNA Therapeutics Recent Development
  • Table 137. Sylentis Company Details
  • Table 138. Sylentis Business Overview
  • Table 139. Sylentis Nucleic Acid Drugs Product
  • Table 140. Sylentis Recent Development
  • Table 141. Arrowhead Company Details
  • Table 142. Arrowhead Business Overview
  • Table 143. Arrowhead Nucleic Acid Drugs Product
  • Table 144. Arrowhead Recent Development
  • Table 145. Silence Therapeutics Company Details
  • Table 146. Silence Therapeutics Business Overview
  • Table 147. Silence Therapeutics Nucleic Acid Drugs Product
  • Table 148. Silence Therapeutics Recent Development
  • Table 149. Dicerna Company Details
  • Table 150. Dicerna Business Overview
  • Table 151. Dicerna Nucleic Acid Drugs Product
  • Table 152. Dicerna Recent Development
  • Table 153. Research Programs/Design for This Report
  • Table 154. Key Data Information from Secondary Sources
  • Table 155. Key Data Information from Primary Sources
  • Table 156. QYR Business Unit and Senior & Team Lead Analysts

List of Figures

  • Figure 1. Global Nucleic Acid Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 2. Global Nucleic Acid Drugs Market Share by Type: 2022
  • Figure 3. Global Nucleic Acid Drugs Market Share by Type: 2029
  • Figure 4. Antisense Oligonucleotides (ASOs) Drugs Features
  • Figure 5. Small Interfering RNA (siRNA) Drugs Features
  • Figure 6. mRNA Drugs Features
  • Figure 7. Global Nucleic Acid Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 8. Global Nucleic Acid Drugs Market Share by Application: 2022
  • Figure 9. Global Nucleic Acid Drugs Market Share by Application: 2029
  • Figure 10. Neuromuscular Diseases Case Studies
  • Figure 11. hATTR Case Studies
  • Figure 12. COVID-19 Case Studies
  • Figure 13. Nucleic Acid Drugs Report Years Considered
  • Figure 14. Global Nucleic Acid Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
  • Figure 15. Global Nucleic Acid Drugs Market Size, (US$ Million), 2018 VS 2023 VS 2029
  • Figure 16. Global Nucleic Acid Drugs Market Share by Region: 2022
  • Figure 17. Global Nucleic Acid Drugs Market Share by Region: 2029
  • Figure 18. Global Nucleic Acid Drugs Market Share by Players in 2022
  • Figure 19. The Top 5Players Market Share by Nucleic Acid Drugs Revenue in 2022
  • Figure 20. North America Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 21. North America Nucleic Acid Drugs Market Share by Type (2018-2029)
  • Figure 22. North America Nucleic Acid Drugs Market Share by Application (2018-2029)
  • Figure 23. North America Nucleic Acid Drugs Market Share by Country (2018-2029)
  • Figure 24. United States Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 25. Canada Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 26. Europe Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 27. Europe Nucleic Acid Drugs Market Share by Type (2018-2029)
  • Figure 28. Europe Nucleic Acid Drugs Market Share by Application (2018-2029)
  • Figure 29. Europe Nucleic Acid Drugs Market Share by Country (2018-2029)
  • Figure 30. Germany Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 31. France Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 32. U.K. Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 33. Italy Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 34. Russia Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 35. China Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 36. China Nucleic Acid Drugs Market Share by Type (2018-2029)
  • Figure 37. China Nucleic Acid Drugs Market Share by Application (2018-2029)
  • Figure 38. Asia Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 39. Asia Nucleic Acid Drugs Market Share by Type (2018-2029)
  • Figure 40. Asia Nucleic Acid Drugs Market Share by Application (2018-2029)
  • Figure 41. Asia Nucleic Acid Drugs Market Share by Region (2018-2029)
  • Figure 42. Japan Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 43. South Korea Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 44. Southeast Asia Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 45. India Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 46. Australia Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 47. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 48. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Type (2018-2029)
  • Figure 49. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Application (2018-2029)
  • Figure 50. Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Country (2018-2029)
  • Figure 51. Brazil Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 52. Mexico Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 53. Middle East Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 54. Africa Nucleic Acid Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed
目次

The global Nucleic Acid Drugs market size is projected to reach US$ 15538.36 million by 2029, from US$ 12486.73 million in 2023, at a CAGR of 3.71% during 2023-2029

The US & Canada market for Nucleic Acid Drugs is estimated to increase from $ 4357.7 million in 2023 to reach $ 7917.6 million by 2029, at a CAGR of 10.46% during the forecast period of 2023 through 2029.

The Europe market for Nucleic Acid Drugs is estimated to increase from $ 5570.25 million in 2023 to reach $ 4295.09million by 2029, at a CAGR of -4.24% during the forecast period of 2023 through 2029.

The global key companies of Nucleic Acid Drugs include: Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2022, the global top five players had a share approximately 97.87% in terms of revenue.

Report Includes:

This report presents an overview of global market for Nucleic Acid Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Nucleic Acid Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nucleic Acid Drugsrevenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Nucleic Acid Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Nucleic Acid Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, BioNTech, Nippon Shinyaku, Moderna Therapeutics, CureVac, and Biogen, etc.

By Company

On Market Company

  • Sarepta Therapeutics
  • Ionis Pharmaceuticals
  • Alnylam
  • Biogen
  • Nippon Shinyaku
  • Sobi
  • Novartis
  • BioNTech
  • Pfizer
  • Moderna Therapeutics
  • Jazz Pharmaceuticals

On Pipeline Company

  • CureVac
  • Regulus Therapeutics
  • ProQR
  • Secarna
  • MiNA Therapeutics
  • Sylentis
  • Arrowhead
  • Silence Therapeutics
  • Dicerna

Segment by Type

  • Antisense Oligonucleotides (ASOs) Drugs
  • Small Interfering RNA (siRNA) Drugs
  • mRNA Drugs
  • Others

Segment by Application

  • Neuromuscular Diseases
  • hATTR
  • COVID-19
  • Other

By Region

  • North America
    • United States
    • Canada
    • China
  • Asia-Pacific
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Latin America, Middle East & Africa
    • Mexico
    • Brazil
    • Rest of Latin America
    • Middle East
    • Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nucleic Acid Drugs companies's competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugsrevenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions.

Table of Contents

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
    • 1.2.2 Antisense Oligonucleotides (ASOs) Drugs
    • 1.2.3 Small Interfering RNA (siRNA) Drugs
    • 1.2.4 mRNA Drugs
  • 1.3 Market by Application
    • 1.3.1 Global Nucleic Acid Drugs Market Share by Application: 2018 VS 2022 VS 2029
    • 1.3.2 Neuromuscular Diseases
    • 1.3.3 hATTR
    • 1.3.4 COVID-19
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Nucleic Acid Drugs Market Perspective (2018-2029)
  • 2.2 Global Nucleic Acid Drugs Growth Trends by Region
    • 2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2018 VS 2022 VS 2029
    • 2.2.2 Nucleic Acid Drugs Historic Market Size by Region (2018-2023)
    • 2.2.3 Nucleic Acid Drugs Forecasted Market Size by Region (2024-2029)
  • 2.3 Nucleic Acid Drugs Market Dynamics
    • 2.3.1 Nucleic Acid Drugs Industry Trends
    • 2.3.2 Nucleic Acid Drugs Market Drivers
    • 2.3.3 Nucleic Acid Drugs Market Challenges
    • 2.3.4 Nucleic Acid Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Revenue Nucleic Acid Drugs by Players
    • 3.1.1 Global Nucleic Acid Drugs Revenue by Players (2018-2023)
    • 3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2018-2023)
  • 3.2 Global Nucleic Acid Drugs Market by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Global Key Players of Nucleic Acid Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
  • 3.4 Global Nucleic Acid Drugs Market Concentration Ratio
    • 3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 5 Companies by Nucleic Acid Drugs Revenue in 2022
  • 3.5 Global Key Players of Nucleic Acid Drugs Head office and Area Served
  • 3.6 Global Key Players of Nucleic Acid Drugs, Product and Application
  • 3.7 Global Key Players Established Date
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Nucleic Acid Drugs Breakdown Data by Type

  • 4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2018-2023)
  • 4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2024-2029)

5 Nucleic Acid Drugs Breakdown Data by Application

  • 5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2018-2023)
  • 5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2024-2029)

6 North America

  • 6.1 North America Nucleic Acid Drugs Market Size (2018-2029)
  • 6.2 North America Nucleic Acid Drugs Market Size by Type
    • 6.2.1 North America Nucleic Acid Drugs Market Size by Type (2018-2023)
    • 6.2.2 North America Nucleic Acid Drugs Market Size by Type (2024-2029)
    • 6.2.3 North America Nucleic Acid Drugs Market Share by Type (2018-2029)
  • 6.3 North America Nucleic Acid Drugs Market Size by Application
    • 6.3.1 North America Nucleic Acid Drugs Market Size by Application (2018-2023)
    • 6.3.2 North America Nucleic Acid Drugs Market Size by Application (2024-2029)
    • 6.3.3 North America Nucleic Acid Drugs Market Share by Application (2018-2029)
  • 6.4 North America Nucleic Acid Drugs Market Size by Country
    • 6.4.1 North America Nucleic Acid Drugs Market Size by Country: 2018 VS 2022 VS 2029
    • 6.4.2 North America Nucleic Acid Drugs Market Size by Country (2018-2023)
    • 6.4.3 North America Nucleic Acid Drugs Market Share by Country (2024-2029)
    • 6.4.4 United States
    • 6.4.5 Canada

7 Europe

  • 7.1 Europe Nucleic Acid Drugs Market Size (2018-2029)
  • 7.2 Europe Nucleic Acid Drugs Market Size by Type
    • 7.2.1 Europe Nucleic Acid Drugs Market Size by Type (2018-2023)
    • 7.2.2 Europe Nucleic Acid Drugs Market Size by Type (2024-2029)
    • 7.2.3 Europe Nucleic Acid Drugs Market Share by Type (2018-2029)
  • 7.3 Europe Nucleic Acid Drugs Market Size by Application
    • 7.3.1 Europe Nucleic Acid Drugs Market Size by Application (2018-2023)
    • 7.3.2 Europe Nucleic Acid Drugs Market Size by Application (2024-2029)
    • 7.3.3 Europe Nucleic Acid Drugs Market Share by Application (2018-2029)
  • 7.4 Europe Nucleic Acid Drugs Market Size by Country
    • 7.4.1 Europe Nucleic Acid Drugs Market Size by Country: 2018 VS 2022 VS 2029
    • 7.4.2 Europe Nucleic Acid Drugs Market Size by Country (2018-2023)
    • 7.4.3 Europe Nucleic Acid Drugs Market Size by Country (2024-2029)
    • 7.4.4 Germany
    • 7.4.5 France
    • 7.4.6 U.K.
    • 7.4.7 Italy
    • 7.4.8 Russia

8 China

  • 8.1 China Nucleic Acid Drugs Market Size (2018-2029)
  • 8.2 China Nucleic Acid Drugs Market Size by Type
    • 8.2.1 China Nucleic Acid Drugs Market Size by Type (2018-2023)
    • 8.2.2 China Nucleic Acid Drugs Market Size by Type (2024-2029)
    • 8.2.3 China Nucleic Acid Drugs Market Share by Type (2018-2029)
  • 8.3 China Nucleic Acid Drugs Market Size by Application
    • 8.3.1 China Nucleic Acid Drugs Market Size by Application (2018-2023)
    • 8.3.2 China Nucleic Acid Drugs Market Size by Application (2024-2029)
    • 8.3.3 China Nucleic Acid Drugs Market Share by Application (2018-2029)

9 Asia (excluding China)

  • 9.1 Asia Nucleic Acid Drugs Market Size (2018-2029)
  • 9.2 Asia Nucleic Acid Drugs Market Size by Type
    • 9.2.1 Asia Nucleic Acid Drugs Market Size by Type (2018-2023)
    • 9.2.2 Asia Nucleic Acid Drugs Market Size by Type (2024-2029)
    • 9.2.3 Asia Nucleic Acid Drugs Market Share by Type (2018-2029)
  • 9.3 Asia Nucleic Acid Drugs Market Size by Application
    • 9.3.1 Asia Nucleic Acid Drugs Market Size by Application (2018-2023)
    • 9.3.2 Asia Nucleic Acid Drugs Market Size by Application (2024-2029)
    • 9.3.3 Asia Nucleic Acid Drugs Market Share by Application (2018-2029)
  • 9.4 Asia Nucleic Acid Drugs Market Size by Region
    • 9.4.1 Asia Nucleic Acid Drugs Market Size by Region: 2018 VS 2022 VS 2029
    • 9.4.2 Asia Nucleic Acid Drugs Market Size by Region (2018-2023)
    • 9.4.3 Asia Nucleic Acid Drugs Market Size by Region (2024-2029)
    • 9.4.4 Japan
    • 9.4.5 South Korea
    • 9.4.6 Southeast Asia
    • 9.4.7 India
    • 9.4.8 Australia

10 Middle East, Africa, and Latin America

  • 10.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size (2018-2029)
  • 10.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type
    • 10.2.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2018-2023)
    • 10.2.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2024-2029)
    • 10.2.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Type (2018-2029)
  • 10.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application
    • 10.3.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2018-2023)
    • 10.3.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2024-2029)
    • 10.3.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Application (2018-2029)
  • 10.4 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country
    • 10.4.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country: 2018 VS 2022 VS 2029
    • 10.4.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2018-2023)
    • 10.4.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2024-2029)
    • 10.4.4 Brazil
    • 10.4.5 Mexico
    • 10.4.6 Middle East
    • 10.4.7 Africa

11 Key Players Profiles

  • 11.1 Sarepta Therapeutics
    • 11.1.1 Sarepta Therapeutics Company Details
    • 11.1.2 Sarepta Therapeutics Business Overview
    • 11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction
    • 11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.1.5 Sarepta Therapeutics Recent Development
  • 11.2 Ionis Pharmaceuticals
    • 11.2.1 Ionis Pharmaceuticals Company Details
    • 11.2.2 Ionis Pharmaceuticals Business Overview
    • 11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction
    • 11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.2.5 Ionis Pharmaceuticals Recent Development
  • 11.3 Alnylam
    • 11.3.1 Alnylam Company Details
    • 11.3.2 Alnylam Business Overview
    • 11.3.3 Alnylam Nucleic Acid Drugs Introduction
    • 11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.3.5 Alnylam Recent Development
  • 11.4 Biogen
    • 11.4.1 Biogen Company Details
    • 11.4.2 Biogen Business Overview
    • 11.4.3 Biogen Nucleic Acid Drugs Introduction
    • 11.4.4 Biogen Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.4.5 Biogen Recent Development
  • 11.5 Nippon Shinyaku
    • 11.5.1 Nippon Shinyaku Company Details
    • 11.5.2 Nippon Shinyaku Business Overview
    • 11.5.3 Nippon Shinyaku Nucleic Acid Drugs Introduction
    • 11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.5.5 Nippon Shinyaku Recent Development
  • 11.6 Sobi
    • 11.6.1 Sobi Company Details
    • 11.6.2 Sobi Business Overview
    • 11.6.3 Sobi Nucleic Acid Drugs Introduction
    • 11.6.4 Sobi Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.6.5 Sobi Recent Development
  • 11.7 Novartis
    • 11.7.1 Novartis Company Details
    • 11.7.2 Novartis Business Overview
    • 11.7.3 Novartis Nucleic Acid Drugs Introduction
    • 11.7.4 Novartis Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.7.5 Novartis Recent Development
  • 11.8 BioNTech
    • 11.8.1 BioNTech Company Details
    • 11.8.2 BioNTech Business Overview
    • 11.8.3 BioNTech Nucleic Acid Drugs Introduction
    • 11.8.4 BioNTech Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.8.5 BioNTech Recent Development
  • 11.9 Pfizer
    • 11.9.1 Pfizer Company Details
    • 11.9.2 Pfizer Business Overview
    • 11.9.3 Pfizer Nucleic Acid Drugs Introduction
    • 11.9.4 Pfizer Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.9.5 Pfizer Recent Development
  • 11.10 Moderna Therapeutics
    • 11.10.1 Moderna Therapeutics Company Details
    • 11.10.2 Moderna Therapeutics Business Overview
    • 11.10.3 Moderna Therapeutics Nucleic Acid Drugs Introduction
    • 11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.10.5 Moderna Therapeutics Recent Development
  • 11.11 Jazz Pharmaceuticals
    • 11.11.1 Jazz Pharmaceuticals Company Details
    • 11.11.2 Jazz Pharmaceuticals Business Overview
    • 11.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Introduction
    • 11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023)
    • 11.11.5 Jazz Pharmaceuticals Recent Development
  • 11.12 CureVac
    • 11.12.1 CureVac Company Details
    • 11.12.2 CureVac Business Overview
    • 11.12.3 CureVac Nucleic Acid Drugs Introduction
    • 11.12.4 CureVac Recent Development
  • 11.13 Regulus Therapeutics
    • 11.13.1 Regulus Therapeutics Company Details
    • 11.13.2 Regulus Therapeutics Business Overview
    • 11.13.3 Regulus Therapeutics Nucleic Acid Drugs Introduction
    • 11.13.4 Regulus Therapeutics Recent Development
  • 11.14 ProQR
    • 11.14.1 ProQR Company Details
    • 11.14.2 ProQR Business Overview
    • 11.14.3 ProQR Nucleic Acid Drugs Introduction
    • 11.14.4 ProQR Recent Development
  • 11.15 Secarna
    • 11.15.1 Secarna Company Details
    • 11.15.2 Secarna Business Overview
    • 11.15.3 Secarna Nucleic Acid Drugs Introduction
    • 11.15.4 Secarna Recent Development
  • 11.16 MiNA Therapeutics
    • 11.16.1 MiNA Therapeutics Company Details
    • 11.16.2 MiNA Therapeutics Business Overview
    • 11.16.3 MiNA Therapeutics Nucleic Acid Drugs Introduction
    • 11.16.4 MiNA Therapeutics Recent Development
  • 11.17 Sylentis
    • 11.17.1 Sylentis Company Details
    • 11.17.2 Sylentis Business Overview
    • 11.17.3 Sylentis Nucleic Acid Drugs Introduction
    • 11.17.4 Sylentis Recent Development
  • 11.18 Arrowhead
    • 11.18.1 Arrowhead Company Details
    • 11.18.2 Arrowhead Business Overview
    • 11.18.3 Arrowhead Nucleic Acid Drugs Introduction
    • 11.18.4 Arrowhead Recent Development
  • 11.19 Silence Therapeutics
    • 11.19.1 Silence Therapeutics Company Details
    • 11.19.2 Silence Therapeutics Business Overview
    • 11.19.3 Silence Therapeutics Nucleic Acid Drugs Introduction
    • 11.19.4 Silence Therapeutics Recent Development
  • 11.20 Dicerna
    • 11.20.1 Dicerna Company Details
    • 11.20.2 Dicerna Business Overview
    • 11.20.3 Dicerna Nucleic Acid Drugs Introduction
    • 11.20.4 Dicerna Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer